Enzymatic Hydrolysis of Pneumococcal Capsular Polysaccharide Renders the Bacterium Vulnerable to Host Defense

Area of Science:

• Microbiology
• Immunology
• Biochemistry

Background:

• Streptococcus pneumoniae is a significant human pathogen responsible for pneumonia, meningitis, and otitis media.
• The capsular polysaccharide (CPS) of S. pneumoniae is crucial for its virulence and colonization.
• Type 3 S. pneumoniae is a particularly virulent serotype, necessitating novel therapeutic strategies.

Purpose of the Study:

• To evaluate the protective potential of a glycoside hydrolase, Pn3Pase, against type 3 Streptococcus pneumoniae.
• To assess Pn3Pase's ability to degrade the type 3 S. pneumoniae capsule.
• To investigate Pn3Pase as an alternative therapeutic approach for pneumococcal infections.

Main Methods:

• Assessing Pn3Pase's capsule degradation activity on live type 3 S. pneumoniae strains.
• Evaluating the effect of Pn3Pase on bacterial susceptibility to phagocytosis by macrophages in vitro.
• Measuring Pn3Pase's impact on complement-mediated killing by neutrophils in vitro.
• Determining Pn3Pase's efficacy in reducing nasopharyngeal colonization and protecting against sepsis in vivo in mouse models.

Main Results:

• Pn3Pase successfully degraded the capsule of type 3 S. pneumoniae.
• In vitro, Pn3Pase treatment enhanced bacterial susceptibility to macrophage phagocytosis and neutrophil complement-mediated killing.
• In vivo, Pn3Pase treatment significantly reduced nasopharyngeal colonization.
• Pn3Pase administration protected mice from sepsis induced by type 3 S. pneumoniae.

Conclusions:

• Pn3Pase is a promising therapeutic agent for combating type 3 Streptococcus pneumoniae infections.
• Enzymatic hydrolysis of pneumococcal CPS offers a viable alternative strategy to combat drug-resistant strains and vaccine escape.
• This approach targets the interaction of pneumococcal CPS with the host at multiple levels, providing a novel treatment avenue.